Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

• Research type

  Research Study

• Full title

  An Interventional Efficacy And Safety, Phase 3, Double-Blind, Parallel Group Study To Investigate Intermittent Prevention Of Menstrual Migraine With Rimegepant Compared With Placebo In Women Participants 18 To 45 Years Of Age

• IRAS ID

  1011792

• Contact name

  Alissa Carmona

• Contact email

  alissa.carmona@pfizer.com

• Sponsor organisation

  Pfizer Inc.

• Clinicaltrials.gov Identifier

  NCT06641466

• Research summary

  This study will explore Rimegepant administered during the peri-menstrual period (PMP) in women for intermittent prevention of menstrual migraine. The purpose of research is to gather information to advance science and medicine. The study duration will be 10 months. Approximately 470 participants will be randomized in the study.

• REC name

  East of England - Essex Research Ethics Committee

• REC reference

  25/EE/0145

• Date of REC Opinion

  26 Aug 2025

• REC opinion

  Further Information Favourable Opinion